National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
In English | En español
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Clinical Trials (PDQ®)
Patient VersionHealth Professional Version
Last Modified: 11/5/2009     First Published: 8/19/2008  
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Clinical Trial Questions?
Get Help:

1-800-4-CANCER or

LiveHelp online chat

Quick Links
Help Using the NCI Clinical Trials Search Form

Educational Materials About Clinical Trials

About NCI's Cancer Clinical Trials Registry

Dictionary of Cancer Terms

NCI Drug Dictionary
Phase III Randomized Study of Pemetrexed Disodium Versus Erlotinib Hydrochloride As Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Related Information
Registry Information

Alternate Title

Pemetrexed or Erlotinib as Second-Line Therapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIIBiomarker/Laboratory analysis, TreatmentActive18 and overNCINCCTG-N0723
MARVEL, N0723, CALGB-30802, CAN-NCIC-BRC4, NCT00738881

Special Category: NCI Web site featured trial, CTSU trial

Objectives

Primary

  1. Compare the progression-free survival of epidermal growth factor receptor (EGFR) FISH-positive or -negative patients with advanced non-small cell lung cancer treated with erlotinib hydrochloride versus pemetrexed disodium as second-line therapy.

Secondary

  1. Compare the overall survival, confirmed response rate, and adverse event profile in these patients based on EGFR-FISH status (positive vs negative).
  2. Compare the progression-free survival, overall survival, confirmed response rate, and adverse event profile in these patients based on EGFR expression as measured by immunohistochemistry (IHC).
  3. Compare the progression-free survival, overall survival, confirmed response rate, and adverse event profile in these patients based on EGFR gene mutation status.
  4. Evaluate the prognostic effect of EGFR copy number, as measured by FISH, on the outcome of these patients.
  5. Evaluate the prognostic effect of EGFR expression, as measured by IHC, on the outcome of these patients.
  6. Evaluate the prognostic effect of EGFR mutation status on the outcome of these patients.
  7. Prospectively test the hypothesis that functionally relevant polymorphisms in the genes encoding for pemetrexed disodium targets, as well as genes encoding for one or more of the key enzymes involved in the transport, activation, and inactivation of pemetrexed disodium, either singly or in combination, play a role in the efficacy and/or toxicity of pemetrexed disodium.
  8. Prospectively test the hypothesis that functionally relevant polymorphisms in the EGFR gene as well as genes encoding for one or more of the key enzymes involved in the metabolism of erlotinib hydrochloride, either singly or in combination, play a role in the efficacy and/or toxicity of erlotinib hydrochloride.
  9. Evaluate proteomic signatures in blood samples as predictors of survival and response to treatment with erlotinib hydrochloride.
  10. Evaluate thymidylate synthase, dihydrofolate reductase, GAR formyltransferase, and methylthioadenosine phosphorylase gene expression in tumor samples, as measured by IHC or quantitative polymerase chain reaction, as predictors of survival and response to treatment with pemetrexed disodium.
  11. Evaluate the Ras mutation status, EGFR mutation status, and epithelial to mesenchymal transition status (E-cadherin expression and vimentin expression) in tumor samples, as measured by IHC, as predictors of survival and response to treatment with erlotinib hydrochloride.

Entry Criteria

Disease Characteristics:

  • Histologically confirmed non-small cell lung cancer (NSCLC), either on initial diagnosis or at the time of disease recurrence/progression
    • Mixed histology allowed if all components are consistent with NSCLC

  • Recurrent or progressive disease

  • Measurable disease, defined as at least one lesion whose longest diameter can be accurately measured as ≥ 2.0 cm by conventional techniques or as ≥ 1.0 cm by spiral CT scan
    • Measurable disease must be outside of any previously irradiated treatment field(s) unless there is disease progression or recurrence within the irradiated field(s)
    • No nonmeasurable disease only, defined as any of the following:
      • Bone lesions
      • Leptomeningeal disease
      • Ascites
      • Pleural/pericardial effusion
      • Inflammatory breast disease
      • Lymphangitis cutis/pulmonis
      • Abdominal masses not confirmed and followed by imaging techniques
      • Cystic lesions
      • Single disease site in prior radiotherapy field

  • Tumor tissue samples must be available and adequate for epidermal growth factor receptor (EGFR) evaluation by FISH

  • Previously treated with only one cytotoxic chemotherapy regimen for advanced disease
    • Neoadjuvant/adjuvant cytotoxic chemotherapy administered < 12 months (from date chemotherapy was started) prior to study entry will be counted as one prior treatment
    • Neoadjuvant/adjuvant chemotherapy administered ≥ 12 months prior to study entry and use of targeted agents (e.g., monoclonal antibodies) will not be counted as one prior treatment

  • No symptomatic serosal effusion (≥ grade 2 dyspnea as measured by CTCAE v3.0) that is not amenable to drainage

  • No brain metastasis, unless the the following criteria are met:
    • Brain metastasis is stable and has been previously treated with either whole-brain radiotherapy or gamma-knife surgery
    • More than 14 days since prior steroid treatment

Prior/Concurrent Therapy:

  • See Disease Characteristics
  • Recovered from prior radiotherapy, except for alopecia
  • No prior radiotherapy to > 25% of bone marrow
  • No prior EGFR tyrosine kinase inhibitors or pemetrexed disodium
  • More than 3 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas)
  • More than 2 weeks since prior immunotherapy, gene therapy, or other biologic therapy
  • More than 2 weeks since prior limited-field radiotherapy (4 weeks for full-field radiotherapy)
  • More than 2 weeks since prior minor surgery*
  • More than 4 weeks since prior major surgery (i.e., laparotomy)* or open biopsy
  • More than 4 weeks since prior hormonal therapy
  • More than 4 weeks since prior and no other concurrent ancillary therapy considered investigational (i.e., utilized for a non-FDA-approved indication and in the context of a research investigation)
  • No aspirin dose ≥ 1.3 g/day for ≥ 10 days before, during, and for ≥ 10 days after treatment with pemetrexed disodium
  • No other concurrent chemotherapy, immunotherapy, hormonal therapy, or radiotherapy
    • Radiotherapy for symptom palliation (e.g., painful pre-existing bony metastasis) allowed
  • No other concurrent anticancer therapy
  • No concurrent major surgery
  • No concurrent antiretroviral therapy
  • No concurrent prophylactic colony-stimulating factors

 [Note: *Insertion of a vascular access device is not considered major or minor surgery]

Patient Characteristics:

  • ECOG performance status 0-2
  • Life expectancy ≥ 12 weeks
  • ANC ≥ 1,500/mm3
  • Platelet count ≥ 100,000/mm3
  • Hemoglobin ≥ 10 g/dL
  • Total bilirubin normal (ULN) OR direct bilirubin normal
  • AST and ALT ≤ 2.5 times ULN
  • INR ≤ 1.5
  • Creatinine clearance ≥ 45 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Able to take folic acid, vitamin B12 supplementation, and dexamethasone
  • No known HIV positivity
  • No clinically significant infection
  • No impaired gastrointestinal (GI) function, inability to swallow pills in the absence of a feeding tube, or GI disease that may significantly alter absorption of oral medications (e.g., ulcerative disease, uncontrolled nausea and vomiting, malabsorption syndromes, or bowel obstruction)
  • No serious condition that, in the opinion of the investigator, would preclude the patient’s ability to complete the study therapy or increase the risk for serious adverse events
  • No other invasive malignant solid tumor or hematologic malignancy, except for any of the following:
    • Prior carcinoma in situ, regardless of organ involvement, or nonmelanoma cutaneous carcinoma that was definitively treated ≥ 3 years ago with no subsequent evidence of recurrence
    • Other prior malignancy diagnosed and definitively treated ≥ 5 years ago with no subsequent evidence of recurrence
      • Prior breast cancer that was definitively treated > 5 years ago allowed provided patient is not receiving aromatase inhibitors
      • Prior low-grade (Gleason score ≤ 6) localized prostate cancer that was diagnosed < 3 years ago allowed
        • Concurrent medications to maintain disease remission allowed
  • No concurrent severe and/or uncontrolled medical condition, including any of the following:
    • Angina pectoris
    • Congestive heart failure within the past 3 months, unless ejection fraction > 40%
    • Myocardial infarction within the past 6 months
    • Cardiac arrhythmia
    • Diabetes mellitus
    • Hypertension
    • Any other severe underlying disease that, in the judgment of the investigator, would preclude study entry
  • No respiratory symptoms > CTCAE grade 1
  • No significant traumatic injury within the past 4 weeks

Expected Enrollment

1196

Outcomes

Primary Outcome(s)

Progression-free survival

Secondary Outcome(s)

Overall survival, confirmed response rate, and adverse event profile based on epidermal growth factor receptor (EGFR)-FISH status (positive vs negative)
Progression-free survival, overall survival, confirmed response rate, and adverse event profile based on EGFR gene mutation status
Progression-free survival, overall survival, confirmed response rate, and adverse event profile based on EGFR expression as measured by immunohistochemistry (IHC)
Prognostic effect of EGFR copy number, EGFR expression, and EGFR mutation status on outcome

Outline

This is a multicenter study. Patients are stratified according to FISH status (negative vs positive), ECOG performance status (0 vs 1 vs 2), gender, smoking status (never smoked vs light smoker [≤ 15 pack years] vs heavy smoker [> 15 pack years]), disease histology (adenocarcinoma vs other), and best response to prior chemotherapy (complete response/partial response vs stable disease vs progressive disease). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

  • Arm II: Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Tumor tissue samples are collected at baseline for correlative laboratory studies, including analysis of epidermal growth factor receptor (EGFR) gene expression by FISH; EGFR protein expression by immunohistochemistry (IHC); EGFR and K-ras mutation status; epithelial to mesenchymal transition status (E-cadherin expression and vimentin expression) by IHC; thymidylate synthase, dihydrofolate reductase, and GAR formyltransferase gene expression by quantitative polymerase chain reaction; and methylthioadenosine phosphorylase gene expression by IHC.

After completion of study therapy, patients are followed every 3 months until disease progression and then every 6 months for up to 5 years.

Trial Contact Information

Trial Lead Organizations

North Central Cancer Treatment Group

Alex Adjei, MD, PhD, Protocol chair
Ph: 716-845-4101; 800-685-6825
Email: alex.adjei@roswellpark.org

Cancer and Leukemia Group B

Martin Edelman, MD, Protocol chair
Ph: 410-328-2703; 800-888-8823
Email: medelman@umm.edu

Eastern Cooperative Oncology Group

David Carbone, MD, PhD, Protocol chair
Ph: 615-936-3524; 800-811-8480
Email: d.carbone@vanderbilt.edu

Southwest Oncology Group

Fred Hirsch, MD, PhD, Protocol chair
Ph: 303-724-3888; 800-473-2288

NCIC-Clinical Trials Group

Geoffrey Liu, MD, Protocol chair
Ph: 416-946-4501 ext. 3428

Trial Sites

U.S.A.
Arizona
  Scottsdale
 Mayo Clinic Scottsdale
 Clinical Trials Office - All Mayo Clinic Locations
Ph: 507-538-7623
Arkansas
  Fort Smith
 Sparks Regional Medical Center
 Clinical Trials Office - Sparks Regional Medical Center
Ph: 479-441-5508
California
  Antioch
 Kaiser Permanente - Deer Valley
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Fremont
 Kaiser Permanente - Fremont
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Hayward
 Kaiser Permanente Medical Center - Hayward
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Marysville
 Tibotec Therapeutics - Division of Ortho Biotech Products, LP
 David Gandara, MD
Ph: 916-734-3772
  Oakland
 Kaiser Permanente Medical Center - Oakland
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Pleasanton
 Valley Care Medical Center
 David Gandara, MD
Ph: 916-734-3772
  Redwood City
 Kaiser Permanente Medical Center - Redwood City
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Richmond
 Kaiser Permanente Medical Center - Richmond
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Roseville
 Kaiser Permanente Medical Center - Roseville
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Sacramento
 Kaiser Permanente Medical Center - Sacramento
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 South Sacramento Kaiser-Permanente Medical Center
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 University of California Davis Cancer Center
 Clinical Trials Office - University of California Davis Cancer Center
Ph: 916-734-3089
  San Francisco
 Kaiser Permanente Medical Center - San Francisco Geary Campus
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  San Jose
 Kaiser Permanente Medical Center - Santa Teresa
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  San Rafael
 Kaiser Foundation Hospital - San Rafael
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Santa Clara
 Kaiser Permanente Medical Center - Santa Clara Kiely Campus
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Santa Rosa
 Kaiser Permanente Medical Center - Santa Rosa
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  South San Francisco
 Kaiser Permanente Medical Center - South San Francisco
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Stockton
 Kaiser Permanente Medical Facility - Stockton
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Truckee
 Tahoe Forest Cancer Center
 David Gandara, MD
Ph: 916-734-3772
  Vacaville
 Kaiser Permanente Medical Center - Vacaville
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Vallejo
 Kaiser Permanente Medical Center - Vallejo
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Walnut Creek
 Kaiser Permanente Medical Center - Walnut Creek
 Louis Fehrenbacher, MD
Ph: 707-651-2577
Colorado
  Aurora
 Aurora Presbyterian Hospital
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
  Boulder
 Boulder Community Hospital
 Clinical Trials Office - Boulder Community Hospital
Ph: 303-938-5253
  Colorado Springs
 Penrose Cancer Center at Penrose Hospital
 Clinical Trials Office - Penrose Cancer Center
Ph: 719-776-5275
  Denver
 CCOP - Colorado Cancer Research Program
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
 Porter Adventist Hospital
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
 Presbyterian - St. Luke's Medical Center
 Clinical Trials Office - Presbyterian - St. Luke's Medical Center
Ph: 303-839-6000
 Rose Medical Center
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
 St. Anthony Central Hospital
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
 St. Joseph Hospital
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
  Englewood
 Swedish Medical Center
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
  Fort Collins
 Poudre Valley Hospital
 Clinical Trials Office - Poudre Valley Hospital
Ph: 970-495-8226
  Grand Junction
 St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
  Greeley
 North Colorado Medical Center
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
  Lone Tree
 Sky Ridge Medical Center
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
  Longmont
 Hope Cancer Care Center at Longmont United Hospital
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
  Loveland
 McKee Medical Center
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
  Pueblo
 St. Mary - Corwin Regional Medical Center
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
  Thornton
 North Suburban Medical Center
 Eduardo Pajon, MD
Ph: 303-399-8020ext2261
  Wheat Ridge
 Exempla Lutheran Medical Center
 Clinical Trials Office - Exempla Lutheran Medical Center
Ph: 303-403-3605
Connecticut
  Bristol
 Bristol Hospital
 Clinical Trials Office - Bristol Hospital
Ph: 860-585-3400
  Middletown
 Middlesex Hospital Cancer Center
 Susanna Hong
Ph: 860-358-2050
Florida
  Boca Raton
 Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus
 Clinical Trials Office - Eugene M. and Christine E. Lynn Cancer Institute
Ph: 561-955-4800
  Jacksonville
 Mayo Clinic - Jacksonville
 Clinical Trials Office - All Mayo Clinic Locations
Ph: 507-538-7623
  Leesburg
 Cancer Centers of Central Florida, PA
 Glenn Mills, MD
Ph: 318-813-1440
Georgia
  Savannah
 Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler
 O. George Negrea, MD
Ph: 912-692-2000
Illinois
  Berwyn
 Hematology Oncology Associates of Illinois - Berwyn
 Jyoti Patel
Ph: 312-695-4549
  Bloomington
 St. Joseph Medical Center
 John Kugler, MD
Ph: 309-243-3605
  Bloomington%
 Illinois CancerCare - Bloomington
 John Kugler, MD
Ph: 309-243-3605
  Canton
 Graham Hospital
 John Kugler, MD
Ph: 309-243-3605
 Illinois CancerCare - Canton
 John Kugler, MD
Ph: 309-243-3605
  Carthage
 Illinois CancerCare - Carthage
 John Kugler, MD
Ph: 309-243-3605
 Memorial Hospital
 John Kugler, MD
Ph: 309-243-3605
  Chicago
 Hematology and Oncology Associates
 Clinical Trails Office - Hematology and Oncology Associates
Ph: 312-695-1301
 Robert H. Lurie Comprehensive Cancer Center at Northwestern University
 Clinical Trials Office - Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Ph: 312-695-1301
 Email: cancer@northwestern.edu
 University of Chicago Cancer Research Center
 Clinical Trials Office - University of Chicago Cancer Research Center
Ph: 773-834-7424
  Decatur
 Decatur Memorial Hospital Cancer Care Institute
 Clinical Trials Office - Decatur Memorial Hospital Cancer Care Institute
Ph: 217-876-6601
  Eureka
 Eureka Community Hospital
 John Kugler, MD
Ph: 309-243-3605
 Illinois CancerCare - Eureka
 John Kugler, MD
Ph: 309-243-3605
  Galesburg
 Galesburg Clinic, PC
 John Kugler, MD
Ph: 309-243-3605
 Galesburg Cottage Hospital
 John Kugler, MD
Ph: 309-243-3605
 Illinois CancerCare - Cottage
 John Kugler, MD
Ph: 309-243-3605
 Illinois CancerCare - Galesburg
 John Kugler, MD
Ph: 309-243-3605
  Havana
 Illinois CancerCare - Havana
 John Kugler, MD
Ph: 309-243-3605
 Mason District Hospital
 John Kugler, MD
Ph: 309-243-3605
  Highland Park
 Kellogg Cancer Care Center
 Jyoti Patel
Ph: 312-695-4549
  Joliet
 Joliet Oncology-Hematology Associates, Limited - West
 Contact Person
Ph: 815-730-3098
 Midwest Center for Hematology/Oncology
 Jyoti Patel
Ph: 312-695-4549
  Kankakee
 Provena St. Mary's Regional Cancer Center - Kankakee
 Riaz Elahi, MD
Ph: 708-873-4500
  Kewanee
 Illinois CancerCare - Kewanee Clinic
 John Kugler, MD
Ph: 309-243-3605
  La Grange
 La Grange Memorial Hospital
 Clinical Trials Office - La Grange Memorial Hospital
Ph: 630-856-7526
  Libertyville
 North Shore Oncology and Hematology Associates, Limited - Libertyville
 Jyoti Patel
Ph: 312-695-4549
  Macomb
 Illinois CancerCare - Macomb
 John Kugler, MD
Ph: 309-243-3605
 McDonough District Hospital
 John Kugler, MD
Ph: 309-243-3605
  Maywood
 Cardinal Bernardin Cancer Center at Loyola University Medical Center
 Clinical Trials Office - Cardinal Bernardin Cancer Center
Ph: 708-226-4357
  Monmouth
 Illinois CancerCare - Monmouth
 John Kugler, MD
Ph: 309-243-3605
 OSF Holy Family Medical Center
 John Kugler, MD
Ph: 309-243-3605
  Naperville
 La Grange Oncology Associates - Geneva
 Jyoti Patel
Ph: 312-695-4549
  Niles
 Cancer Care and Hematology Specialists of Chicagoland - Niles
 Jyoti Patel
Ph: 312-695-4549
  Normal
 BroMenn Regional Medical Center
 John Kugler, MD
Ph: 309-243-3605
 Community Cancer Center
 John Kugler, MD
Ph: 309-243-3605
 Illinois CancerCare - Community Cancer Center
 John Kugler, MD
Ph: 309-243-3605
  Ottawa
 Community Hospital of Ottawa
 John Kugler, MD
Ph: 309-243-3605
 Oncology Hematology Associates of Central Illinois, PC - Ottawa
 John Kugler, MD
Ph: 309-243-3605
  Pekin
 Cancer Treatment Center at Pekin Hospital
 John Kugler, MD
Ph: 309-243-3605
 Illinois CancerCare - Pekin
 John Kugler, MD
Ph: 309-243-3605
  Peoria
 CCOP - Illinois Oncology Research Association
 John Kugler, MD
Ph: 309-243-3605
 Methodist Medical Center of Illinois
 Clinical Trials Office - Methodist Medical Center of Illinois
Ph: 309-243-3000
 Oncology Hematology Associates of Central Illinois, PC - Peoria
 John Kugler, MD
Ph: 309-243-3605
 OSF St. Francis Medical Center
 John Kugler, MD
Ph: 309-243-3605
 John Kugler, MD
Ph: 309-243-3605
 Proctor Hospital
 John Kugler, MD
Ph: 309-243-3605
  Peru
 Illinois CancerCare - Peru
 John Kugler, MD
Ph: 309-243-3605
 Illinois Valley Community Hospital
 John Kugler, MD
Ph: 309-243-3605
  Princeton
 Illinois CancerCare - Princeton
 John Kugler, MD
Ph: 309-243-3605
  Skokie
 Hematology Oncology Associates - Skokie
 Jyoti Patel
Ph: 312-695-4549
  Spring Valley
 Illinois CancerCare - Spring Valley
 John Kugler, MD
Ph: 309-243-3605
 St. Margaret's Hospital
 John Kugler, MD
Ph: 309-243-3605
  Springfield
 Regional Cancer Center at Memorial Medical Center
 Clinical Trials Office - Regional Cancer Center at Memorial Medical Center
Ph: 217-788-4233
Indiana
  Beech Grove
 St. Francis Hospital and Health Centers - Beech Grove Campus
 Howard Gross, MD
Ph: 937-832-1093
  Richmond
 Reid Hospital & Health Care Services
 Howard Gross, MD
Ph: 937-832-1093
Iowa
  Ames
 McFarland Clinic, PC
 Clinical Trials Office - McFarland Clinic, PC
Ph: 515-239-2621
  Bettendorf
 Hematology Oncology Associates of the Quad Cities
 Shobha Chitneni, MD, MBBS
Ph: 563-355-7733
  Cedar Rapids
 Cedar Rapids Oncology Associates
 Clinical Trials Office - Cedar Rapids Oncology Associates
Ph: 319-363-2690
 Mercy Regional Cancer Center at Mercy Medical Center
 Martin Wiesenfeld, MD
Ph: 319-363-8303
  Clive
 Medical Oncology and Hematology Associates - West Des Moines
 Robert Behrens
Ph: 515-875-9713
  Davenport
 Genesis Medical Center - West Campus
 George Kovach, MD
Ph: 563-421-1960
 Genesis Regional Cancer Center at Genesis Medical Center
 George Kovach, MD
Ph: 563-421-1960
  Des Moines
 CCOP - Iowa Oncology Research Association
 Robert Behrens
Ph: 515-244-7586
888-244-6061
 John Stoddard Cancer Center at Iowa Lutheran Hospital
 Clinical Trials Office - John Stoddard Cancer Center at Iowa Lutheran Hospital
Ph: 515-241-8704
 John Stoddard Cancer Center at Iowa Methodist Medical Center
 Clinical Trials Office - John Stoddard Cancer Center at Iowa Methodist Medical Center
Ph: 515-241-6727
 Medical Oncology and Hematology Associates at John Stoddard Cancer Center
 Robert Behrens
Ph: 515-282-2921
 Medical Oncology and Hematology Associates at Mercy Cancer Center
 Robert Behrens
Ph: 515-643-8740
 Mercy Cancer Center at Mercy Medical Center - Des Moines
 Robert Behrens
Ph: 515-643-8206
888-221-4849
  Ottumwa
 McCreery Cancer Center at Ottumwa Regional
 Robert Behrens
Ph: 641-684-2946
  Sioux City
 Mercy Medical Center - Sioux City
 Donald Wender, MD, PhD
Ph: 712-252-0088
 Siouxland Hematology-Oncology Associates, LLP
 Donald Wender, MD, PhD
Ph: 712-252-0088
 St. Luke's Regional Medical Center
 Donald Wender, MD, PhD
Ph: 712-252-0088
  Waterloo
 Covenant Cancer Treatment Center
 Clinical Trials Office - Covenant Cancer Treatment Center
Ph: 319-272-2070
Kansas
  Chanute
 Cancer Center of Kansas, PA - Chanute
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Dodge City
 Cancer Center of Kansas, PA - Dodge City
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  El Dorado
 Cancer Center of Kansas, PA - El Dorado
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Fort Scott
 Cancer Center of Kansas - Fort Scott
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Independence
 Cancer Center of Kansas-Independence
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Kingman
 Cancer Center of Kansas, PA - Kingman
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Lawrence
 Lawrence Memorial Hospital
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Liberal
 Southwest Medical Center
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Newton
 Cancer Center of Kansas, PA - Newton
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Overland Park
 Menorah Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
 Saint Luke's Hospital - South
 Rakesh Gaur, MD
Ph: 816-823-0555
  Parsons
 Cancer Center of Kansas, PA - Parsons
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Pratt
 Cancer Center of Kansas, PA - Pratt
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Salina
 Cancer Center of Kansas, PA - Salina
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Shawnee Mission
 Shawnee Mission Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
  Topeka
 Cotton-O'Neil Cancer Center
 Clinical Trials Office - Cotton-O'Neil Cancer Center
Ph: 785-270-4963
  Wellington
 Cancer Center of Kansas, PA - Wellington
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Wichita
 Associates in Womens Health, PA - North Review
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
 Cancer Center of Kansas, PA - Wichita
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
 Cancer Center of Kansas, PA - Medical Arts Tower
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
 CCOP - Wichita
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
 Via Christi Cancer Center at Via Christi Regional Medical Center
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
  Winfield
 Cancer Center of Kansas, PA - Winfield
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
Louisiana
  Baton Rouge
 Mary Bird Perkins Cancer Center - Baton Rouge
 Robert Veith
Ph: 225-767-0847
 Pennington Cancer Center at Baton Rouge General
 Clinical Trials Office - Pennington Cancer Center at Baton Rouge General
Ph: 225-381-6451
  Mansfield
 DeSoto Regional Hospital
 Glenn Mills, MD
Ph: 318-813-1440
  Monroe
 Louisiana State University Health Sciences Center - Monroe
 Glenn Mills, MD
Ph: 318-813-1440
  New Orleans
 MBCCOP - LSU Health Sciences Center
 Robert Veith
Ph: 504-568-5151
 Medical Center of Louisiana - New Orleans
 Robert Veith
Ph: 504-903-2311
  Shreveport
 Feist-Weiller Cancer Center at Louisiana State University Health Sciences
 Clinical Trials Office - Feist-Weiller Cancer Center at Louisiana State University Health Sciences
Ph: 318-813-1412
 Highland Clinic
 Glenn Mills, MD
Ph: 318-813-1440
Maryland
  Baltimore
 Greater Baltimore Medical Center Cancer Center
 Clinical Trials Office - Greater Baltimore Medical Center Cancer Center
Ph: 443-849-3706
  Easton
 Shore Regional Cancer Center at Memorial Hospital - Easton
 Mary DeShields, MD
Ph: 410-819-3332
Massachusetts
  Attleboro
 Sturdy Memorial Hospital
 Michael Vasconcelles, MD
Ph: 617-632-5301
  Boston
 Boston University Cancer Research Center
 Clinical Trials Office - Boston University Cancer Research Center
Ph: 617-353-7571
 Tufts-NEMC Cancer Center
 Gary Strauss
Ph: 617-636-6100
  Brighton
 Caritas St. Elizabeth's Medical Center
 Paul Hesketh, MD
Ph: 617-789-2317
  Hyannis
 Cape Cod Hospital
 Kelly Swanson
Ph: 508-771-1800
Michigan
  Adrian
 Hickman Cancer Center at Bixby Medical Center
 Clinical Trials Office - Hickman Cancer Center at Bixby Medical Center
Ph: 517-265-0116
  Ann Arbor
 CCOP - Michigan Cancer Research Consortium
 Philip Stella, MD
Ph: 734-712-1000
 Saint Joseph Mercy Cancer Center
 Philip Stella, MD
Ph: 734-712-1000
  Battle Creek
 Battle Creek Health System Cancer Care Center
 Marianne Lange, MD
Ph: 616-977-6243
  Big Rapids
 Mecosta County Medical Center
 Marianne Lange, MD
Ph: 616-977-6243
  Dearborn
 Oakwood Cancer Center at Oakwood Hospital and Medical Center
 Clinical Trials Office - Oakwood Cancer Center at Oakwood Hospital and Medical Center
Ph: 313-593-8090
  Flint
 Genesys Hurley Cancer Institute
 Clinical Trials Office - Genesys Hurley Cancer Institute
Ph: 810-762-8057
 Hurley Medical Center
 Clinical Trials Office - Hurley Medical Center
Ph: 810-762-8057
  Grand Rapids
 Butterworth Hospital at Spectrum Health
 Marianne Lange, MD
Ph: 616-977-6243
 CCOP - Grand Rapids
 Marianne Lange, MD
Ph: 616-977-6243
 Lacks Cancer Center at Saint Mary's Health Care
 Marianne Lange, MD
Ph: 616-977-6243
  Grosse Pointe Woods
 Van Elslander Cancer Center at St. John Hospital and Medical Center
 Clincial Trials Office - Van Elslander Cancer Center at St. John Hospital and Medical Center
Ph: 313-343-3166
  Kalamazoo
 Borgess Medical Center
 Raymond Lord, MD
Ph: 269-373-7458
 Bronson Methodist Hospital
 Raymond Lord, MD
Ph: 269-373-7458
 West Michigan Cancer Center
 Clinical Trials Office - West Michigan Cancer Center
Ph: 269-373-7458
  Lambertville
 Haematology-Oncology Associates of Ohio and Michigan, PC
 Paul Schaefer, MD
Ph: 419-479-5605
  Lansing
 Sparrow Regional Cancer Center
 Clinical Trials Office - Sparrow Regional Cancer Center
Ph: 517-364-2890
  Livonia
 St. Mary Mercy Hospital
 Philip Stella, MD
Ph: 734-712-1000
  Monroe
 Community Cancer Center of Monroe
 Paul Schaefer, MD
Ph: 419-479-5605
 Mercy Memorial Hospital - Monroe
 Paul Schaefer, MD
Ph: 419-479-5605
  Muskegon
 Mercy General Health Partners
 Marianne Lange, MD
Ph: 616-977-6243
  Pontiac
 St. Joseph Mercy Oakland
 Philip Stella, MD
Ph: 734-712-1000
  Port Huron
 Mercy Regional Cancer Center at Mercy Hospital
 Philip Stella, MD
Ph: 734-712-1000
  Saginaw
 Seton Cancer Institute at Saint Mary's - Saginaw
 Clinical Trials Office - Seton Cancer Institute - Saginaw
Ph: 989-776-8411
  Traverse City
 Munson Medical Center
 Marianne Lange, MD
Ph: 616-977-6243
  Warren
 St. John Macomb Hospital
 Philip Stella, MD
Ph: 734-712-1000
  Wyoming
 Metro Health Hospital
 Marianne Lange, MD
Ph: 616-977-6243
Minnesota
  Alexandria
 Donald Jurgens
Ph: 320-229-4907
  Bemidji
 MeritCare Bemidji
 Preston Steen, MD
Ph: 701-234-2397
  Burnsville
 Fairview Ridges Hospital
 Patrick Flynn, MD
Ph: 612-863-8585
  Coon Rapids
 Mercy and Unity Cancer Center at Mercy Hospital
 Patrick Flynn, MD
Ph: 612-863-8585
  Duluth
 CCOP - Duluth
 Daniel Nikcevich, MD, PhD
Ph: 218-786-3625
 Duluth Clinic Cancer Center - Duluth
 Clinical Trials Office - Duluth Clinic Cancer Center - Duluth
Ph: 218-786-3308
 Miller - Dwan Medical Center
 Daniel Nikcevich, MD, PhD
Ph: 218-786-3625
  Edina
 Fairview Southdale Hospital
 Clinical Trials Office - Fairview Southdale Hospital
Ph: 612-625-3650
  Fridley
 Mercy and Unity Cancer Center at Unity Hospital
 Patrick Flynn, MD
Ph: 612-863-8585
  Hutchinson
 Hutchinson Area Health Care
 Daniel Anderson
Ph: 320-234-5000
800-454-3903
  Lichfield
 Meeker County Memorial Hospital
 Clinical Trials Office - Meeker County Memorial Hospital
Ph: 320-693-4520
  Maplewood
 HealthEast Cancer Care at St. John's Hospital
 Daniel Anderson
Ph: 651-232-7970
 Minnesota Oncology Hematology, PA - Maplewood
 Patrick Flynn, MD
Ph: 612-863-8585
  Minneapolis
 Hennepin County Medical Center - Minneapolis
 Clinical Trials Office - Hennepin County Medical Center - Minneapolis
Ph: 612-873-5911
 Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
 Clinical Trials Office - Virginia Piper Cancer Institute
Ph: 612-863-5654
  Robbinsdale
 Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
 Clinical Trials Office - Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
Ph: 763-520-1893
  Rochester
 Mayo Clinic Cancer Center
 Clinical Trials Office - All Mayo Clinic Locations
Ph: 507-538-7623
  Saint Cloud
 CentraCare Clinic - River Campus
 Donald Jurgens
Ph: 320-229-4907
 Coborn Cancer Center
 Donald Jurgens
Ph: 320-229-4907
  Saint Louis Park
 CCOP - Metro-Minnesota
 Patrick Flynn, MD
Ph: 612-863-8585
 Park Nicollet Cancer Center
 Patrick Flynn, MD
Ph: 612-863-8585
  Saint Paul
 United Hospital
 Patrick Flynn, MD
Ph: 612-863-8585
  Shakopee
 St. Francis Cancer Center at St. Francis Medical Center
 Patrick Flynn, MD
Ph: 612-863-8585
  St. Paul
 Regions Hospital Cancer Care Center
 Clinical Trials Office - Regions Hospital Cancer Care Center
Ph: 651-254-1517
  Waconia
 Ridgeview Medical Center
 Patrick Flynn, MD
Ph: 612-863-8585
  Willmar
 Willmar Cancer Center at Rice Memorial Hospital
 Joseph Ryan, MD
Ph: 320-231-6359
  Woodbury
 Minnesota Oncology Hematology, PA - Woodbury
 Patrick Flynn, MD
Ph: 612-863-8585
Mississippi
  Kessler AFB
 Keesler Air Force Base Medical Center
 Louis Varner
Ph: 228-377-2086
Missouri
  Kansas City
 CCOP - Kansas City
 Rakesh Gaur, MD
Ph: 816-823-0555
 North Kansas City Hospital
 Rakesh Gaur, MD
Ph: 816-823-0555
 Parvin Radiation Oncology
 Rakesh Gaur, MD
Ph: 816-823-0555
 Research Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
 Saint Luke's Cancer Institute at Saint Luke's Hospital
 Rakesh Gaur, MD
Ph: 816-823-0555
 St. Joseph Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
 Truman Medical Center - Hospital Hill
 Rakesh Gaur, MD
Ph: 816-823-0555
  Lee's Summit
 Saint Luke's East - Lee's Summit
 Rakesh Gaur, MD
Ph: 816-823-0555
  Liberty
 Liberty Hospital
 Rakesh Gaur, MD
Ph: 816-823-0555
  Saint Joseph
 Heartland Regional Medical Center
 Rakesh Gaur, MD
Ph: 816-823-0555
  Saint Louis
 Arch Medical Services, Incorporated at Center for Cancer Care and Research
 Alan Lyss, MD
Ph: 314-996-5514
 Missouri Baptist Cancer Center
 Alan Lyss, MD
Ph: 314-996-5514
 Saint Louis University Cancer Center
 Clinical Trials Office - Saint Louis University Cancer Center
Ph: 314-977-4440
  Springfield
 CCOP - Cancer Research for the Ozarks
 Robert Carolla
Ph: 417-269-4520
 Hulston Cancer Center at Cox Medical Center South
 Robert Carolla
Ph: 417-269-5257
 St. John's Regional Health Center
 Robert Carolla
Ph: 417-820-2000
Montana
  Billings
 Billings Clinic - Downtown
 Clinical Trials Office - Billings Clinic - Downtown
Ph: 800-996-2663
 Email: research@billingsclinic.org
 CCOP - Montana Cancer Consortium
 Benjamin Marchello, MD
Ph: 406-238-6290
 Hematology-Oncology Centers of the Northern Rockies - Billings
 Benjamin Marchello, MD
Ph: 406-238-6290
 Northern Rockies Radiation Oncology Center
 Benjamin Marchello, MD
Ph: 406-238-6290
 St. Vincent Healthcare Cancer Care Services
 Benjamin Marchello, MD
Ph: 406-238-6290
  Bozeman
 Bozeman Deaconess Cancer Center
 Benjamin Marchello, MD
Ph: 406-238-6290
  Butte
 St. James Healthcare Cancer Care
 Benjamin Marchello, MD
Ph: 406-238-6290
  Great Falls
 Benjamin Marchello, MD
Ph: 406-238-6290
 Big Sky Oncology
 Clinical Trail Office - Big Sky Oncology
Ph: 406-731-8217
 Great Falls Clinic - Main Facility
 Benjamin Marchello, MD
Ph: 406-238-6290
 Sletten Cancer Institute at Benefis Healthcare
 Grant Harrer, MD, FACP, CCTI
Ph: 406-731-8100
  Havre
 Northern Montana Hospital
 Benjamin Marchello, MD
Ph: 406-238-6290
  Helena
 St. Peter's Hospital
 Benjamin Marchello, MD
Ph: 406-238-6290
  Kalispell
 Glacier Oncology, PLLC
 Benjamin Marchello, MD
Ph: 406-238-6290
 Kalispell Medical Oncology at KRMC
 Benjamin Marchello, MD
Ph: 406-238-6290
 Kalispell Regional Medical Center
 Benjamin Marchello, MD
Ph: 406-238-6290
  Missoula
 Community Medical Center
 Benjamin Marchello, MD
Ph: 406-238-6290
 Guardian Oncology and Center for Wellness
 Benjamin Marchello, MD
Ph: 406-238-6290
 Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
 Clinical Trials Office - Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Ph: 406-329-7029
 Montana Cancer Specialists at Montana Cancer Center
 Clinical Trials Office - Montana Cancer Specialists at Montana Cancer Center
Ph: 406-238-6962
Nebraska
  Kearney
 Good Samaritan Cancer Center at Good Samaritan Hospital
 Clinical Trials Office - Good Samaritan Cancer Center at Good Samaritan Hospital
Ph: 308-865-7963
  Lincoln
 Cancer Resource Center - Lincoln
 Alan Berg, MD
Ph: 402-420-7000
  Omaha
 Alegant Health Cancer Center at Bergan Mercy Medical Center
 Clinical Trials Office - Alegant Health Cancer Center at Bergen Mercy Medical Center
Ph: 402-398-6060
 CCOP - Missouri Valley Cancer Consortium
 Gamini Soori, MD, FACP, FRCP, MBA
Ph: 402-393-3110
 Creighton University Medical Center
 Clinical Trials Office - Creighton University Medical Center
Ph: 402-280-4100
 Immanuel Medical Center
 Gamini Soori, MD, FACP, FRCP, MBA
Ph: 402-393-3110
New Jersey
  East Orange
 Veterans Affairs Medical Center - East Orange
 Basil Kasimis, MD, DSc
Ph: 973-395-7809
  Flemington
 Hunterdon Regional Cancer Center at Hunterdon Medical Center
 Kenneth Blankstein, MD
Ph: 908-788-6100
  Marlton
 Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
 Clinical Trials Office - Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
Ph: 888-847-8823
  Red Bank
 Booker Cancer Center at Riverview Medical Center
 Denis Fitzgerald, MD
Ph: 732-530-8666
  Voorhees
 Fox Chase Virtua Health Cancer Program at Virtua West Jersey
 Michael Entmacher, MD
Ph: 609-702-1900
New York
  Buffalo
 Roswell Park Cancer Institute
 Clinical Trials Office - Roswell Park Cancer Institute
Ph: 877-275-7724
  East Syracuse
 CCOP - Hematology-Oncology Associates of Central New York
 Jeffrey Kirshner, MD
Ph: 315-472-7504
  Glens Falls
 Charles R. Wood Cancer Center at Glens Falls Hospital
 Clinical Trials Office - Charles R. Wood Cancer Center at Glens Falls Hospital
Ph: 518-926-6700
  Rochester
 James P. Wilmot Cancer Center at University of Rochester Medical Center
 Richard Fisher, MD
Ph: 585-275-0842
  Syracuse
 SUNY Upstate Medical University Hospital
 Clinical Trials Office - SUNY Upstate Medical University Hospital
Ph: 315-464-5476
 Veterans Affairs Medical Center - Syracuse
 Ajeet Gajra, MD
Ph: 315-425-4666
North Carolina
  Charlotte
 Presbyterian Cancer Center at Presbyterian Hospital
 Clinical Trials Office - Presbyterian Cancer Center at Presbyterian Hospital
Ph: 704-384-5369
  Goldsboro
 Wayne Memorial Hospital, Incorporated
 James Atkins, MD
Ph: 919-580-0000
  Hendersonville
 Pardee Memorial Hospital
 James Radford, MD
Ph: 828-692-8045
  Rutherfordton
 Rutherford Hospital
 James Bearden, MD
Ph: 864-560-6812
North Dakota
  Bismarck
 Bismarck Cancer Center
 Edward Wos, DO
Ph: 701-323-5741
 Medcenter One Hospital Cancer Care Center
 Edward Wos, DO
Ph: 701-323-5741
 Mid Dakota Clinic, PC
 Clinical Trials Office - Mid Dakota Clinic, PC
Ph: 701-530-6950
 St. Alexius Medical Center Cancer Center
 Clinical Trials Office - St. Alexius Medical Center Cancer Center
Ph: 701-530-6950
  Fargo
 CCOP - MeritCare Hospital
 Preston Steen, MD
Ph: 701-234-2397
 MeritCare Broadway
 Preston Steen, MD
Ph: 701-234-2397
  Grand Forks
 Altru Cancer Center at Altru Hospital
 Clinical Trails Office - Altru Cancer Center at Altru Hospital
Ph: 701-780-6520
Ohio
  Akron
 McDowell Cancer Center at Akron General Medical Center
 Esther Rehmus, MD
Ph: 330-344-6505
  Bowling Green
 Wood County Oncology Center
 Paul Schaefer, MD
Ph: 419-479-5605
  Canton
 Aultman Cancer Center at Aultman Hospital
 Clinical Trials Office - Aultman Cancer Center at Aultman Hospital
Ph: 330-363-6891
  Clyde
 North Coast Cancer Care - Clyde
 Paul Schaefer, MD
Ph: 419-479-5605
  Columbus
 Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
 Ohio State University Cancer Clinical Trial Matching Service
Ph: 866-627-7616
 Email: osu@emergingmed.com
  Dayton
 CCOP - Dayton
 Howard Gross, MD
Ph: 937-832-1093
 David L. Rike Cancer Center at Miami Valley Hospital
 Clinical Trials Office - David L. Rike Cancer Center at Miami Valley Hospital
Ph: 937-208-2079
 Good Samaritan Hospital
 Howard Gross, MD
Ph: 937-832-1093
 Grandview Hospital
 Howard Gross, MD
Ph: 937-832-1093
 Samaritan North Cancer Care Center
 Howard Gross, MD
Ph: 937-832-1093
  Elyria
 Hematology Oncology Center
 Paul Schaefer, MD
Ph: 419-479-5605
  Findlay
 Blanchard Valley Medical Associates
 Howard Gross, MD
Ph: 937-832-1093
  Franklin
 Middletown Regional Hospital
 Howard Gross, MD
Ph: 937-832-1093
  Greenville
 Wayne Hospital
 Howard Gross, MD
Ph: 937-832-1093
  Kettering
 Charles F. Kettering Memorial Hospital
 Clinical Trials Office - Charles F. Kettering Memorial Hospital
Ph: 937-298-3399 ext. 57556
  Lima
 Lima Memorial Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
  Maumee
 Northwest Ohio Oncology Center
 Paul Schaefer, MD
Ph: 419-479-5605
 Paul Schaefer, MD
Ph: 419-479-5605
 St. Luke's Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
  Oregon
 St. Charles Mercy Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 Toledo Clinic - Oregon
 Paul Schaefer, MD
Ph: 419-479-5605
  Sandusky
 North Coast Cancer Care, Incorporated
 Paul Schaefer, MD
Ph: 419-479-5605
  Sylvania
 Flower Hospital Cancer Center
 Clinical Trials Office - Flower Hospital Cancer Center
Ph: 419-824-1842
  Tiffin
 Mercy Hospital of Tiffin
 Paul Schaefer, MD
Ph: 419-479-5605
  Toledo
 CCOP - Toledo Community Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 Medical University of Ohio Cancer Center
 Clinical Trials Office - Medical University of Ohio Cancer Center
Ph: 419-383-6583
 St. Anne Mercy Hospital
 Paul Schaefer, MD
Ph: 419-479-5605
 St. Vincent Mercy Medical Center
 Paul Schaefer, MD
Ph: 419-479-5605
 Toledo Clinic, Incorporated - Main Clinic
 Paul Schaefer, MD
Ph: 419-479-5605
 Toledo Hospital
 Clinical Trials Office - Toledo Hospital
Ph: 419-824-1842
  Troy
 UVMC Cancer Care Center at Upper Valley Medical Center
 Clinical Trials Office - UVMC Cancer Care Center at Upper Valley Medical Center
Ph: 937-440-4842
  Wauseon
 Fulton County Health Center
 Clinical Trials Office - Fulton County Health Center
Ph: 419-330-2708
  Wilmington
 Clinton Memorial Hospital
 Howard Gross, MD
Ph: 937-832-1093
  Xenia
 Ruth G. McMillan Cancer Center at Greene Memorial Hospital
 Howard Gross, MD
Ph: 937-832-1093
Oklahoma
  Tulsa
 Natalie Warren Bryant Cancer Center at St. Francis Hospital
 Mark Olsen, MD, PhD
Ph: 918-499-2000
Pennsylvania
  Allentown
 Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
 Suresh Nair, MD
Ph: 610-402-0512
  Bryn Mawr
 Bryn Mawr Hospital
 Clinical Trials Office - Bryn Mawr Hospital
Ph: 610-645-2680
  Danville
 Geisinger Cancer Institute at Geisinger Health
 Clinical Trials Office - Geisinger Cancer Institute
Ph: 570-271-5251
  Dubois
 Oncology Hematology Associates of Northern Pennsylvania, PC at Hahne Regional Cancer Center
 Carmine Marchioli, MD
Ph: 814-375-3535
  Hazleton
 Geisinger Hazleton Cancer Center
 Rajiv Panikkar
Ph: 570-459-2901
  Paoli
 Cancer Center of Paoli Memorial Hospital
 Clinical Trials Office - Cancer Center of Paoli Memorial Hospital
Ph: 610-648-1637
  Philadelphia
 Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
 Clinical Trials Office - Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Ph: 215-955-6084
  Reading
 McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
 Clinical Trials Office - McGlinn Family Regional Cancer Center
Ph: 610-988-9323
  Scranton
 Hematology and Oncology Associates of Northeastern Pennsylvania
 Martin Hyzinski, MD
Ph: 570-558-3020
 Mercy Hospital Cancer Center - Scranton
 Martin Hyzinski, MD
Ph: 570-558-3020
  State College
 Geisinger Medical Group - Scenery Park
 Rajiv Panikkar
Ph: 814-231-4560
 Mount Nittany Medical Center
 Philip Lowry, MD
Ph: 978-343-5048
  Wilkes-Barre
 Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
 Clinical Trials Office - Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
Ph: 570-271-5251
  Wynnewood
 CCOP - Main Line Health
 Paul Gilman, MD
Ph: 610-645-2000
 Lankenau Cancer Center at Lankenau Hospital
 Paul Gilman, MD
Ph: 610-645-2000
South Carolina
  Anderson
 AnMed Cancer Center
 Clinical Trials Office - AnMed Cancer Center
Ph: 864-512-1000
  Spartanburg
 CCOP - Upstate Carolina
 Clinical Trials Office - CCOP - Upstate Carolina
Ph: 800-486-5941
 Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
 Clinical Trials Office - Gibbs Regional Cancer Center
Ph: 800-486-5941
South Dakota
  Rapid City
 Rapid City Regional Hospital
 Richard Tenglin
Ph: 605-719-2360
  Sioux Falls
 Avera Cancer Institute
 Loren Tschetter, MD
Ph: 605-328-8000
 Medical X-Ray Center, PC
 Loren Tschetter, MD
Ph: 605-328-8000
 Sanford Cancer Center at Sanford USD Medical Center
 Clinical Trials Office - Sanford Cancer Center
Ph: 605-328-1367
Virginia
  Danville
 Danville Regional Medical Center
 Clinical Trials Office - Danville Regional Medical Center
Ph: 434-799-3753
  Fredericksburg
 Fredericksburg Oncology, Incorporated
 Paul Schaefer, MD
Ph: 419-479-5605
  Martinsville
 Ravenel Oncology Center at Memorial Hospital of Martinsville and Henry County
 Arthur Sleeper, MD
Ph: 276-666-7200
  Richmond
 Virginia Commonwealth University Massey Cancer Center
 Clinical Trials Office -Virginia Commonwealth University Massey Cancer Center
Ph: 804-628-1939
West Virginia
  Charleston
 West Virginia University Health Sciences Center - Charleston
 Steven Jubelirer, MD
Ph: 304-388-8380
Wisconsin
  Oconomowoc
 Regional Cancer Center at Oconomowoc Memorial Hospital
 Clinical Trials Office - Regional Cancer Center at Oconomowoc Memorial Hospital
Ph: 262-928-7878
  Waukesha
 Waukesha Memorial Hospital Regional Cancer Center
 Clinical Trials Office - Waukesha Memorial Hospital Regional Cancer Center
Ph: 262-928-7632
Wyoming
  Casper
 Rocky Mountain Oncology
 Benjamin Marchello, MD
Ph: 406-238-6290
  Sheridan
 Welch Cancer Center at Sheridan Memorial Hospital
 Benjamin Marchello, MD
Ph: 406-238-6290
Canada
Saskatchewan
  Regina
 Allan Blair Cancer Centre at Pasqua Hospital
 Haji Chalchal
Ph: 306-766-2203

Related Information

Featured trial article

Registry Information
Official Title A Phase III Biomarker Validation study of Second-line Therapy in Patients With Advanced Non- Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib
Trial Start Date 2008-10-01
Trial Completion Date 2011-05-03 (estimated)
Registered in ClinicalTrials.gov NCT00738881
Date Submitted to PDQ 2008-08-11
Information Last Verified 2009-11-05
NCI Grant/Contract Number CA25224

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Back to TopBack to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov